Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT811 in Advanced Solid Tumors and Gliomas
NCT04089449Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Nov 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prt811 in solid tumor, high-grade glioma (HGG), central nervous system lymphoma and 2 more, sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicities at Day 21, Maximally Tolerated Dose at 2 years and 1 more. Started Nov 2019; status: completed.
02
Drugs
prt811
03
Conditions
solid tumorhigh-grade glioma (HGG)central nervous system lymphomaglioblastoma multiforme (GBM)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04089449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089449.